ROCKVILLE, Md., April 10, 2008 (PRIME NEWSWIRE) -- Cytomedix, Inc. (AMEX:GTF), today announced that it will be exhibiting at the 21st Annual Symposium on Advanced Wound Care (SAWC) from April 24 through April 27, 2008 at the San Diego Convention Center in San Diego, Ca.
The SAWC is the largest gathering of multidisciplinary wound care clinicians in the United States. The conference targets physicians, nurses, physical therapists, researchers, podiatrists, dieticians, and members of the medical industry involved in wound healing or wound care issues. The conference provides attendees who study and treat wounds with state-of-the-art reviews of clinical problems and research information.
"We look forward to exhibiting at this prestigious event," said Kshitij Mohan, Ph.D., Chairman and Chief Executive Officer of Cytomedix, Inc. "Our participation in this symposium comes at a time when we are proceeding with the launch of our AutoloGel(tm) System as planned, and provides an excellent venue for demonstrating this unique wound management system utilizing platelet rich plasma (PRP) gel for use in a wide variety of exuding wounds, including diabetic ulcers, leg ulcers and pressure ulcers and other surgically or mechanically debrided wounds."
ABOUT CYTOMEDIX
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for use on wounds and other applications. The current offering is the AutoloGel(tm) System, a process that utilizes an autologous platelet gel composed of multiple growth factors, other platelet releasates, and fibrin matrix. Additional information regarding Cytomedix is available at: http://www.cytomedix.com.
SAFE HARBOR STATEMENT
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, the success of new sales initiatives, governmental regulation, acceptance by the medical community, and competition.
These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.